NantKwest Inc (NK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH327397D
- Pages: 42
- October 2018
- Total Views:1120
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
NantKwest Inc (NantKwest), a subsidiary of NantWorks LLC, formerly Conkwest Inc, is a clinical-stage immunotherapy company that develops therapeutic treatments for cancer, infectious diseases, and inflammatory diseases. The company utilizes its immuno-oncology NK platform to destroy the tumor cells through direct killing or antibody-mediated killing or target activated killing. Its haNK, aNK and taNK platforms addresses the certain limitations of T cell therapies that include the reduction of risk of serious cytokine storms reported after T cell therapy. The company provides targeted therapeutic areas such as hematological cancers, solid tumors and cancer stem cells, viral, fungal and bacterial infections, inflammatory diseases, and others. The company operates through its offices located in Culver, Woburn, San Diego, the US, and others. NantKwest is headquartered in San Diego, California, the US.
NantKwest Inc (NK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
NantKwest Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
NantKwest Inc, Medical Devices Deals, 2012 to YTD 2018 10
NantKwest Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
NantKwest Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Viracta Therapeutics Raises USD18.4 Million in Series B Financing 12
Conkwest Raises USD 6.5 Million In Venture Financing 13
Partnerships 14
Altor BioScience Enters into Co-Development Agreement with NantKwest 14
NantBioScience and NantKwest Enters into R&D Agreement with National Cancer Institute 15
NantKwest Enters into Agreement with NanoCav 16
Sorrento Therapeutics Enters into Collaboration Agreement with Conkwest 17
Licensing Agreements 18
NantKwest Enters into Licensing Agreement with Viracta Therapeutics 18
NantKwest Amends its Licensing Agreement for NK-92 19
Inex Bio Enters into Licensing Agreement with Conkwest 20
Equity Offering 21
NantKwest Completes IPO 21
NantKwest Raises USD17 Million in Private Placement of Shares 23
Conkwest Raises USD71 Million in Private Placement of Shares 24
Conkwest Raises USD6.4 Million in Private Placement of Shares upon Exercise of Warrants 25
Conkwest to Raise USD48 Million in Private Placement of Common Stock 26
Acquisition 27
Conkwest Acquires Remaining 77.8% Stake in Inex Bio for USD8 Million 27
Conkwest Acquires 22.2% Stake in Inex Bio for USD0.25 Million 28
NantKwest Inc-Key Competitors 29
NantKwest Inc-Key Employees 30
NantKwest Inc-Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Corporate Communications 32
Jun 19, 2018: NantKwest Appoints Sonja Nelson As Chief Financial Officer 32
Sep 22, 2017: NantKwest Builds Financial and Commercial Expertise with the Appointment of Fred Driscoll to Its Board of Directors 33
Product News 34
06/06/2017: NantKwest Expands NANT Cancer Vaccine Program With Additional Clinical Trials Announced Addressing Multiple Cancer Types Across All Stages of Disease 34
Product Approvals 35
May 09, 2017: NantKwest and NantCell Announce FDA Authorization for the NANT Cancer Vaccine Clinical Trials, the First Novel Combination of Innate and Adaptive Immunotherapy in Patients with Pancreatic Cancer 35
Mar 20, 2017: NantKwest Announces FDA Grant of Orphan Drug Designation for the Company's aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma 36
Clinical Trials 37
Feb 13, 2018: Nantkwest and Frankfurt University Hospital Announce First in Human Dosing of off-the-Shelf HER2.taNK (Car-natural Killer) Cell Therapy in Glioblastoma 37
Oct 02, 2017: NantKwest Announces Successful First in Human Administration of CD16 High Affinity Natural Killer Cells 38
Jul 31, 2017: NantKwest Announces Durable Complete Responses in Phase I Trial of aNK Cell Therapy in Patients with Relapsed Hematological Malignancies 39
Jan 23, 2017: Landmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment of Cancer 40
Other Significant Developments 41
Jan 04, 2018: NantKwest to Host 3rd Annual Investor/Analyst Day Highlighting A Record Number of 15 INDs Authorized in 2017 Covering 12 Tumor Types with First In-Human Clinical Data of Safety and Early Signs of Clinical Activity of the Nant Cancer Vaccine 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42
List Of Figure
List of Figures
NantKwest Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
NantKwest Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
NantKwest Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
NantKwest Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
NantKwest Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
NantKwest Inc, Deals By Therapy Area, 2012 to YTD 2018 9
NantKwest Inc, Medical Devices Deals, 2012 to YTD 2018 10
NantKwest Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Viracta Therapeutics Raises USD18.4 Million in Series B Financing 12
Conkwest Raises USD 6.5 Million In Venture Financing 13
Altor BioScience Enters into Co-Development Agreement with NantKwest 14
NantBioScience and NantKwest Enters into R&D Agreement with National Cancer Institute 15
NantKwest Enters into Agreement with NanoCav 16
Sorrento Therapeutics Enters into Collaboration Agreement with Conkwest 17
NantKwest Enters into Licensing Agreement with Viracta Therapeutics 18
NantKwest Amends its Licensing Agreement for NK-92 19
Inex Bio Enters into Licensing Agreement with Conkwest 20
NantKwest Completes IPO 21
NantKwest Raises USD17 Million in Private Placement of Shares 23
Conkwest Raises USD71 Million in Private Placement of Shares 24
Conkwest Raises USD6.4 Million in Private Placement of Shares upon Exercise of Warrants 25
Conkwest to Raise USD48 Million in Private Placement of Common Stock 26
Conkwest Acquires Remaining 77.8% Stake in Inex Bio for USD8 Million 27
Conkwest Acquires 22.2% Stake in Inex Bio for USD0.25 Million 28
NantKwest Inc, Key Competitors 29
NantKwest Inc, Key Employees 30
NantKwest Inc, Other Locations 31
NantKwest Inc, Subsidiaries 31
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
NantKwest Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
NantKwest Inc (NantKwest), a subsidiary of NantWorks LLC, formerly Conkwest Inc, is a clinical-stage immunotherapy company that develops therapeutic treatments for cancer, infectious diseases, and inflammatory diseases. The company utilizes its immuno-oncology NK platform to destroy the tumor cells through direct killing or antibody-mediated killing or target activated killing. Its haNK, aNK and taNK platforms addresses the certain limitations of T cell therapies that include the reduction of risk of serious cytokine storms reported after T cell therapy. The company provides targeted therapeutic areas such as hematological cancers, solid tumors and cancer stem cells, viral, fungal and bacterial infections, inflammatory diseases, and others. The company operates through its offices located in Culver, Woburn, San Diego, the US, and others. NantKwest is headquartered in San Diego, California, the US.
NantKwest Inc (NK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
NantKwest Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
NantKwest Inc, Medical Devices Deals, 2012 to YTD 2018 10
NantKwest Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
NantKwest Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Viracta Therapeutics Raises USD18.4 Million in Series B Financing 12
Conkwest Raises USD 6.5 Million In Venture Financing 13
Partnerships 14
Altor BioScience Enters into Co-Development Agreement with NantKwest 14
NantBioScience and NantKwest Enters into R&D Agreement with National Cancer Institute 15
NantKwest Enters into Agreement with NanoCav 16
Sorrento Therapeutics Enters into Collaboration Agreement with Conkwest 17
Licensing Agreements 18
NantKwest Enters into Licensing Agreement with Viracta Therapeutics 18
NantKwest Amends its Licensing Agreement for NK-92 19
Inex Bio Enters into Licensing Agreement with Conkwest 20
Equity Offering 21
NantKwest Completes IPO 21
NantKwest Raises USD17 Million in Private Placement of Shares 23
Conkwest Raises USD71 Million in Private Placement of Shares 24
Conkwest Raises USD6.4 Million in Private Placement of Shares upon Exercise of Warrants 25
Conkwest to Raise USD48 Million in Private Placement of Common Stock 26
Acquisition 27
Conkwest Acquires Remaining 77.8% Stake in Inex Bio for USD8 Million 27
Conkwest Acquires 22.2% Stake in Inex Bio for USD0.25 Million 28
NantKwest Inc-Key Competitors 29
NantKwest Inc-Key Employees 30
NantKwest Inc-Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Corporate Communications 32
Jun 19, 2018: NantKwest Appoints Sonja Nelson As Chief Financial Officer 32
Sep 22, 2017: NantKwest Builds Financial and Commercial Expertise with the Appointment of Fred Driscoll to Its Board of Directors 33
Product News 34
06/06/2017: NantKwest Expands NANT Cancer Vaccine Program With Additional Clinical Trials Announced Addressing Multiple Cancer Types Across All Stages of Disease 34
Product Approvals 35
May 09, 2017: NantKwest and NantCell Announce FDA Authorization for the NANT Cancer Vaccine Clinical Trials, the First Novel Combination of Innate and Adaptive Immunotherapy in Patients with Pancreatic Cancer 35
Mar 20, 2017: NantKwest Announces FDA Grant of Orphan Drug Designation for the Company's aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma 36
Clinical Trials 37
Feb 13, 2018: Nantkwest and Frankfurt University Hospital Announce First in Human Dosing of off-the-Shelf HER2.taNK (Car-natural Killer) Cell Therapy in Glioblastoma 37
Oct 02, 2017: NantKwest Announces Successful First in Human Administration of CD16 High Affinity Natural Killer Cells 38
Jul 31, 2017: NantKwest Announces Durable Complete Responses in Phase I Trial of aNK Cell Therapy in Patients with Relapsed Hematological Malignancies 39
Jan 23, 2017: Landmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment of Cancer 40
Other Significant Developments 41
Jan 04, 2018: NantKwest to Host 3rd Annual Investor/Analyst Day Highlighting A Record Number of 15 INDs Authorized in 2017 Covering 12 Tumor Types with First In-Human Clinical Data of Safety and Early Signs of Clinical Activity of the Nant Cancer Vaccine 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42
List Of Figure
List of Figures
NantKwest Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
NantKwest Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
NantKwest Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
NantKwest Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
NantKwest Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
NantKwest Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
NantKwest Inc, Deals By Therapy Area, 2012 to YTD 2018 9
NantKwest Inc, Medical Devices Deals, 2012 to YTD 2018 10
NantKwest Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Viracta Therapeutics Raises USD18.4 Million in Series B Financing 12
Conkwest Raises USD 6.5 Million In Venture Financing 13
Altor BioScience Enters into Co-Development Agreement with NantKwest 14
NantBioScience and NantKwest Enters into R&D Agreement with National Cancer Institute 15
NantKwest Enters into Agreement with NanoCav 16
Sorrento Therapeutics Enters into Collaboration Agreement with Conkwest 17
NantKwest Enters into Licensing Agreement with Viracta Therapeutics 18
NantKwest Amends its Licensing Agreement for NK-92 19
Inex Bio Enters into Licensing Agreement with Conkwest 20
NantKwest Completes IPO 21
NantKwest Raises USD17 Million in Private Placement of Shares 23
Conkwest Raises USD71 Million in Private Placement of Shares 24
Conkwest Raises USD6.4 Million in Private Placement of Shares upon Exercise of Warrants 25
Conkwest to Raise USD48 Million in Private Placement of Common Stock 26
Conkwest Acquires Remaining 77.8% Stake in Inex Bio for USD8 Million 27
Conkwest Acquires 22.2% Stake in Inex Bio for USD0.25 Million 28
NantKwest Inc, Key Competitors 29
NantKwest Inc, Key Employees 30
NantKwest Inc, Other Locations 31
NantKwest Inc, Subsidiaries 31
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
NantKwest Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020